Liquidia Co. (NASDAQ:LQDA) Shares Sold by Vestal Point Capital LP

Vestal Point Capital LP lessened its position in shares of Liquidia Co. (NASDAQ:LQDA) by 18.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,500,000 shares of the company’s stock after selling 330,000 shares during the quarter. Liquidia accounts for 1.1% of Vestal Point Capital LP’s portfolio, making the stock its 25th largest position. Vestal Point Capital LP owned approximately 1.95% of Liquidia worth $15,000,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of LQDA. Quest Partners LLC purchased a new position in Liquidia during the 2nd quarter worth approximately $27,000. Hilltop National Bank purchased a new stake in Liquidia in the second quarter valued at $33,000. Deuterium Capital Management LLC acquired a new stake in Liquidia during the 2nd quarter worth about $120,000. Clear Harbor Asset Management LLC acquired a new stake in Liquidia during the 3rd quarter worth about $100,000. Finally, Signaturefd LLC lifted its holdings in shares of Liquidia by 38,400.0% in the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after buying an additional 9,984 shares during the period. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Stock Up 1.7 %

NASDAQ:LQDA opened at $11.61 on Friday. Liquidia Co. has a one year low of $6.82 and a one year high of $16.99. The stock has a 50 day moving average price of $10.70 and a 200 day moving average price of $11.37.

Analysts Set New Price Targets

A number of brokerages have issued reports on LQDA. HC Wainwright reissued a “buy” rating and issued a $29.00 price target on shares of Liquidia in a report on Thursday, November 14th. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of Liquidia in a research report on Thursday, November 14th. BTIG Research lowered their price target on Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, August 19th. Finally, Bank of America reduced their target price on Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Insiders Place Their Bets

In other news, insider Rajeev Saggar sold 2,260 shares of Liquidia stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the sale, the insider now owns 207,383 shares of the company’s stock, valued at approximately $2,304,025.13. The trade was a 1.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Russell Schundler sold 2,576 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $28,619.36. Following the sale, the general counsel now directly owns 486,048 shares of the company’s stock, valued at approximately $5,399,993.28. This trade represents a 0.53 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,551 shares of company stock valued at $236,021 in the last three months. 30.10% of the stock is currently owned by insiders.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).